AbbVie acquired Syndesi Therapeutics for up to $1B ($130M upfront plus $870M in milestones). The deal added Syndesi's portfolio of SV2A modulators including lead molecule SDI-118, being evaluated for cognitive impairment in neuropsychiatric and neurodegenerative diseases such as Alzheimer's and major depressive disorder.
Key facts
AnnouncedMar 01, 2022
ClosedMar 01, 2022
Deal value$1.0B
Deal typeAcquisition/Merger
Therapeutic areaCognitive impairment in Alzheimer's, MDD, neurodegenerative disorders
IndicationsCognitive impairment in Alzheimer's, MDD, neurodegenerative disorders
Key assetsSDI-118
MechanismSynaptic vesicle protein 2A (SV2A) modulator